Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents

Recruiting now · Phase 2/Phase 3

Conditions studied: Mature B-cell Non-Hodgkin Lymphoma

In brief

The purpose of this study is to test whether intensive chemotherapy combined with early, adequate, and intensive use of Rituximab for aggressive B-NHL in children and adolescents can improve the EFS and OS compared with the historical study CCCG-BNHL-2015.

Key facts

Study ID

NCT07168980

Run by

Children's Cancer Group, China

People needed

87

Starts

2025-07-01

Expected to finish

2030-06-30

Last updated by the study team

2026-06-04

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histology or cytologically confirmed mature B-cell NHL/AL(Burkitt, DLBCL, PMLBL,or aggressive mature B-cell NHL non other specified or specifiable)
• Able to comply with scheduled follow-up and with management of toxicity
• Signed informed consent

You may not qualify if…

• Follicular lymphoma, MALT and nodular marginal zone are not included into this therapeutic study
• Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology.
• Evidence of pregnancy or lactation period. Past or current anti-cancer treatment except corticosteroids during less than one week.
• Exclusion Criteria related to Rituximab :
• Tumor cell negative for CD20
• Prior exposure to rituximab
• Hepatitis B carrier status history of HBV or positive serology.

Where it is running

• Shanghai Children's Medical Center — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.